{"id":341163,"date":"2025-08-20T14:08:54","date_gmt":"2025-08-20T14:08:54","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-bridgebio-pharma\/"},"modified":"2025-08-20T14:08:54","modified_gmt":"2025-08-20T14:08:54","slug":"how-to-buy-bridgebio-pharma","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/","title":{"rendered":"How to buy BridgeBio Pharma, Inc. (BBIO) shares &#8211; Investment in BridgeBio Pharma, Inc. (BBIO) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334117,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-341163","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy BridgeBio Pharma, Inc. (BBIO) Shares - Investment in BridgeBio Pharma, Inc. (BBIO) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy BridgeBio Pharma, Inc. (BBIO) Shares - Investment in BridgeBio Pharma, Inc. (BBIO) Stock"},"description":"Learn how to buy BridgeBio Pharma, Inc. (BBIO) shares and invest in this innovative biotech company. Complete guide with price analysis, risks, and 2025-2030 forecasts.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to buy BridgeBio Pharma, Inc. (BBIO) shares and invest in this innovative biotech company. Complete guide with price analysis, risks, and 2025-2030 forecasts."},"intro":"Thinking about investing in a company that's literally changing lives through genetic medicine? BridgeBio Pharma represents one of the most exciting opportunities in biotech right now. With groundbreaking treatments for rare genetic diseases and a commercial portfolio that's just starting to gain traction, this stock could be your ticket to both financial growth and making a real difference in healthcare. Let's break down everything you need to know about getting involved with BBIO.","intro_source":{"label":"Intro","type":"text","formatted_value":"Thinking about investing in a company that's literally changing lives through genetic medicine? BridgeBio Pharma represents one of the most exciting opportunities in biotech right now. With groundbreaking treatments for rare genetic diseases and a commercial portfolio that's just starting to gain traction, this stock could be your ticket to both financial growth and making a real difference in healthcare. Let's break down everything you need to know about getting involved with BBIO."},"body_html":"<h2>\ud83d\udcc8 Current Market Position and Entry Point Analysis<\/h2> <p>As of August 20, 2025, BridgeBio Pharma (BBIO) is trading at <strong>$48.91<\/strong> per share. This price represents a fascinating juncture for investors - the company has already demonstrated massive growth potential but still maintains significant upside according to analyst projections.<\/p> <p><strong>Critical Date Alert:<\/strong> Mark your calendar for <strong>early November 2025<\/strong> - that's when BridgeBio is expected to release its Q3 earnings report. Historically, these quarterly updates have been major catalysts for price movement.<\/p> <p><strong>Earnings Impact Pattern Analysis:<\/strong><br\/> Looking at recent performance, BridgeBio's Q2 2025 results on August 5th showed a net loss per share of $0.95, which actually missed expectations by $0.27. However, the market reaction was surprisingly positive because revenue beat estimates by $15 million, reaching $110.6 million total. This pattern suggests that investors are more focused on revenue growth and commercial traction than short-term profitability - a common theme in high-growth biotech.<\/p>  [cta_green text=\"Start trading\"]<h2>\ud83d\udd04 6-Month Price Journey: Rollercoaster with Rewards<\/h2> <p>BridgeBio's stock has been on an absolute tear over the past six months, delivering one of the most impressive performances in the biotech sector:<\/p> <ul> <li><strong>March 2025:<\/strong> The stock traded between $30.55-$37.94, closing the month with a modest -0.95% decline as investors digested previous gains<a href=\"https:\/\/stockscan.io\/stocks\/BBIO\/price-history\">(StockScan)<\/a>.<\/li> <li><strong>April 2025:<\/strong> Momentum returned with a powerful +10.96% surge, breaking through key resistance levels as trading volume exploded to 63.9 million shares<a href=\"https:\/\/stockscan.io\/stocks\/BBIO\/price-history\">(StockScan)<\/a>.<\/li> <li><strong>May 2025:<\/strong> A temporary -10.71% pullback provided a buying opportunity, with the stock finding support around $31.77 amid continued high volume<a href=\"https:\/\/stockscan.io\/stocks\/BBIO\/price-history\">(StockScan)<\/a>.<\/li> <li><strong>June 2025:<\/strong> The standout month with a massive +26.07% explosion, driven by strong Attruby prescription data and positive clinical updates<a href=\"https:\/\/stockscan.io\/stocks\/BBIO\/price-history\">(StockScan)<\/a>.<\/li> <li><strong>July 2025:<\/strong> Continued strength with +8.77% gains, reaching new 52-week highs of $48.68 as institutional interest grew<a href=\"https:\/\/stockscan.io\/stocks\/BBIO\/price-history\">(StockScan)<\/a>.<\/li> <li><strong>August 2025:<\/strong> Maintaining momentum around $49-51 levels, representing a spectacular <strong>+67% cumulative gain<\/strong> from March lows to current prices<a href=\"https:\/\/stockscan.io\/stocks\/BBIO\/price-history\">(StockScan)<\/a>.<\/li> <\/ul> <p>This performance isn't just good - it's exceptional. BBIO has delivered a <strong>+101% return over the past year<\/strong> while the broader market gained only 16.6%<a href=\"https:\/\/marketchameleon.com\/Overview\/BBIO\/Summary\/\">(Market Chameleon)<\/a>.<\/p>  <h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2> <p>Based on current analyst consensus and company fundamentals, here's what you can expect:<\/p> <ul> <li><strong>2025 Year-End:<\/strong> Target range <strong>$52-62<\/strong> - The consensus price target sits at $61.69 (24.22% upside) with some analysts projecting as high as $95<a href=\"https:\/\/stockanalysis.com\/stocks\/bbio\/forecast\/\">(Stock Analysis)<\/a>. \u2192 <strong>STRONG BUY<\/strong><\/li> <li><strong>2026 Projection:<\/strong> <strong>$44-52<\/strong> range - Some divergence emerges here with estimates between $35.01-$50.36, reflecting typical biotech volatility<a href=\"https:\/\/altindex.com\/ticker\/bbio\/price-prediction\">(AltIndex)<\/a>.<\/li> <li><strong>2028 Outlook:<\/strong> While specific 2028 forecasts aren't widely published, the trajectory suggests <strong>$55-70<\/strong> potential if current commercial success continues.<\/li> <li><strong>2030 Long-Term:<\/strong> <strong>$22-36<\/strong> range - Longer-term forecasts show compression due to patent concerns and competition, but this represents excellent returns from current levels<a href=\"https:\/\/gov.capital\/stock\/bbio-stock\/\">(Gov Capital)<\/a>.<\/li> <\/ul> <p>The key takeaway? Near-term momentum is incredibly strong, making now an excellent entry point for investors comfortable with biotech volatility.<\/p>  <h2>\u26a0\ufe0f Risk Assessment: What Could Go Wrong<\/h2> <ul> <li><strong>High Volatility Risk:<\/strong> BBIO has a beta of 0.88-0.94, meaning it can swing wildly on clinical trial news or regulatory decisions<a href=\"https:\/\/marketchameleon.com\/Overview\/BBIO\/Summary\/\">(Market Chameleon)<\/a>. A failed trial could easily drop the stock 30-50% in days.<\/li> <li><strong>Regulatory Dependency:<\/strong> The entire business hinges on FDA and EMA approvals. Any delays or rejections for pipeline drugs would be catastrophic.<\/li> <li><strong>Cash Burn Concerns:<\/strong> Despite recent revenue growth, the company still reported a $0.95 per share loss last quarter. They need continued commercial success to reach profitability<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/08\/05\/3127793\/0\/en\/BridgeBio-Reports-Second-Quarter-2025-Financial-Results-and-Business-Updates.html\">(Globe Newswire)<\/a>.<\/li> <li><strong>Competition Intensification:<\/strong> Larger pharma companies are increasingly targeting rare genetic diseases, potentially eroding BridgeBio's first-mover advantage.<\/li> <\/ul>  <h2>\ud83d\udfe2 Positive Signals: Why The Bull Case Is Strong<\/h2> <ul> <li><strong>Commercial Traction:<\/strong> Attruby generated $71.5 million in Q2 2025 net product revenue with 3,751 unique prescriptions already - nearly doubling from previous quarter<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/08\/05\/3127793\/0\/en\/BridgeBio-Reports-Second-Quarter-2025-Financial-Results-and-Business-Updates.html\">(Globe Newswire)<\/a>.<\/li> <li><strong>Financial Strength:<\/strong> $540.6 million cash position plus $300 million recent royalty monetization provides massive runway for development<a href=\"https:\/\/investor.bridgebio.com\/news\/news-details\/2025\/BridgeBio-Raises-300-Million-Through-Partial-Capped-Monetization-of-BEYONTTRA-European-Royalty\/default.aspx\">(BridgeBio Investor)<\/a>.<\/li> <li><strong>Pipeline Depth:<\/strong> Multiple Phase 3 programs including BBP-418 fully enrolled ahead of schedule, creating numerous potential catalysts<a href=\"https:\/\/investor.bridgebio.com\/overview\/default.aspx\">(BridgeBio Overview)<\/a>.<\/li> <li><strong>Analyst Support:<\/strong> 16 analysts cover BBIO with 7 Strong Buy and 9 Buy ratings - zero Hold or Sell recommendations<a href=\"https:\/\/stockanalysis.com\/stocks\/bbio\/forecast\/\">(Stock Analysis)<\/a>.<\/li> <\/ul>  <h2>\ud83c\udfaf Beginner Trader Action Plan<\/h2> <p><strong>Today's Smart Moves:<\/strong><\/p> <ol> <li><strong>Start Small<\/strong>: Allocate no more than 3-5% of your portfolio to BBIO initially - biotech is inherently risky<\/li> <li><strong>Dollar-Cost Average<\/strong>: Consider buying in increments rather than one lump sum to smooth out volatility<\/li> <li><strong>Set Alert for November<\/strong>: Mark your calendar for Q3 earnings - this could be your best entry point if there's a post-earnings dip<\/li> <li><strong>Monitor Volume<\/strong>: High volume days often precede major moves - use them as additional entry signals<\/li> <\/ol> <p><strong>Humorous Veteran Insight:<\/strong> \"Trading BBIO is like dating a brilliant scientist - incredibly rewarding but prone to dramatic mood swings based on experimental results. Don't propose marriage on the first date!\"<\/p>  <h2>\u2705 Step-by-Step: How to Buy BridgeBio Pharma, Inc. (BBIO) Shares<\/h2> <table> <thead> <tr><th>Step<\/th><th>Action<\/th><th>Why It Matters<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Choose a Trading Platform<\/td><td>Ensure it offers NASDAQ access and reasonable commission fees<\/td><\/tr> <tr><td>2<\/td><td>Complete Account Funding<\/td><td>Start with an amount you're comfortable risking - even $100 can get you started<\/td><\/tr> <tr><td>3<\/td><td>Search for \"BBIO\"<\/td><td>Use the ticker symbol, not the company name, for accurate results<\/td><\/tr> <tr><td>4<\/td><td>Select Order Type<\/td><td>Use limit orders to control your entry price rather than market orders<\/td><\/tr> <tr><td>5<\/td><td>Review and Confirm<\/td><td>Double-check order details and fees before finalizing<\/td><\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Why Pocket Option Makes Sense for BBIO Trading<\/h2> <p>For investors looking to trade BridgeBio Pharma, Inc. (BBIO) stock, Pocket Option offers several distinct advantages that align perfectly with biotech investing:<\/p> <ul> <li><strong>Minimum Deposit Flexibility<\/strong>: With just $5 required to start, you can test strategies with minimal risk before committing larger amounts to this volatile sector.<\/li> <li><strong>Rapid Account Verification<\/strong>: The 1-minute KYC process means you can capitalize on breaking news or sudden price movements without waiting days for account approval.<\/li> <li><strong>Diverse Withdrawal Options<\/strong>: Over 100 withdrawal methods ensure you can access profits quickly when BBIO makes those characteristic biotech spikes.<\/li> <\/ul> <p>This platform structure is particularly valuable for trading stocks like BBIO that can move 10-20% on single news events, allowing you to enter and exit positions with maximum flexibility.<\/p>  <h2>\ud83e\uddec BridgeBio in 2025: Genetic Medicine Pioneer<\/h2> <p>BridgeBio Pharma has established itself as a commercial-stage biopharmaceutical company focused exclusively on developing transformative medicines for genetic diseases and certain cancers<a href=\"https:\/\/investor.bridgebio.com\/overview\/default.aspx\">(BridgeBio Overview)<\/a>. Founded in 2015, the company operates globally with a presence across North America and Europe.<\/p> <p>The company's business model combines internal drug discovery with strategic partnerships, currently marketing four approved medicines while maintaining a robust pipeline across precision cardiorenal, mendelian diseases, precision oncology, and gene therapy<a href=\"https:\/\/investor.bridgebio.com\/overview\/default.aspx\">(BridgeBio Overview)<\/a>.<\/p> <p><strong>2025 Interesting Fact<\/strong>: BridgeBio's drug Attruby achieved something remarkable - it generated 3,751 unique patient prescriptions within just nine months of FDA approval, with adoption growing at nearly 100% quarter-over-quarter<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/08\/05\/3127793\/0\/en\/BridgeBio-Reports-Second-Quarter-2025-Financial-Results-and-Business-Updates.html\">(Globe Newswire)<\/a>. This commercial velocity is virtually unprecedented in the rare disease space and demonstrates both medical need and execution excellence.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Current Market Position and Entry Point Analysis<\/h2>\n<p>As of August 20, 2025, BridgeBio Pharma (BBIO) is trading at <strong>$48.91<\/strong> per share. This price represents a fascinating juncture for investors &#8211; the company has already demonstrated massive growth potential but still maintains significant upside according to analyst projections.<\/p>\n<p><strong>Critical Date Alert:<\/strong> Mark your calendar for <strong>early November 2025<\/strong> &#8211; that&#8217;s when BridgeBio is expected to release its Q3 earnings report. Historically, these quarterly updates have been major catalysts for price movement.<\/p>\n<p><strong>Earnings Impact Pattern Analysis:<\/strong><br \/> Looking at recent performance, BridgeBio&#8217;s Q2 2025 results on August 5th showed a net loss per share of $0.95, which actually missed expectations by $0.27. However, the market reaction was surprisingly positive because revenue beat estimates by $15 million, reaching $110.6 million total. This pattern suggests that investors are more focused on revenue growth and commercial traction than short-term profitability &#8211; a common theme in high-growth biotech.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd04 6-Month Price Journey: Rollercoaster with Rewards<\/h2>\n<p>BridgeBio&#8217;s stock has been on an absolute tear over the past six months, delivering one of the most impressive performances in the biotech sector:<\/p>\n<ul>\n<li><strong>March 2025:<\/strong> The stock traded between $30.55-$37.94, closing the month with a modest -0.95% decline as investors digested previous gains<a href=\"https:\/\/stockscan.io\/stocks\/BBIO\/price-history\">(StockScan)<\/a>.<\/li>\n<li><strong>April 2025:<\/strong> Momentum returned with a powerful +10.96% surge, breaking through key resistance levels as trading volume exploded to 63.9 million shares<a href=\"https:\/\/stockscan.io\/stocks\/BBIO\/price-history\">(StockScan)<\/a>.<\/li>\n<li><strong>May 2025:<\/strong> A temporary -10.71% pullback provided a buying opportunity, with the stock finding support around $31.77 amid continued high volume<a href=\"https:\/\/stockscan.io\/stocks\/BBIO\/price-history\">(StockScan)<\/a>.<\/li>\n<li><strong>June 2025:<\/strong> The standout month with a massive +26.07% explosion, driven by strong Attruby prescription data and positive clinical updates<a href=\"https:\/\/stockscan.io\/stocks\/BBIO\/price-history\">(StockScan)<\/a>.<\/li>\n<li><strong>July 2025:<\/strong> Continued strength with +8.77% gains, reaching new 52-week highs of $48.68 as institutional interest grew<a href=\"https:\/\/stockscan.io\/stocks\/BBIO\/price-history\">(StockScan)<\/a>.<\/li>\n<li><strong>August 2025:<\/strong> Maintaining momentum around $49-51 levels, representing a spectacular <strong>+67% cumulative gain<\/strong> from March lows to current prices<a href=\"https:\/\/stockscan.io\/stocks\/BBIO\/price-history\">(StockScan)<\/a>.<\/li>\n<\/ul>\n<p>This performance isn&#8217;t just good &#8211; it&#8217;s exceptional. BBIO has delivered a <strong>+101% return over the past year<\/strong> while the broader market gained only 16.6%<a href=\"https:\/\/marketchameleon.com\/Overview\/BBIO\/Summary\/\">(Market Chameleon)<\/a>.<\/p>\n<h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2>\n<p>Based on current analyst consensus and company fundamentals, here&#8217;s what you can expect:<\/p>\n<ul>\n<li><strong>2025 Year-End:<\/strong> Target range <strong>$52-62<\/strong> &#8211; The consensus price target sits at $61.69 (24.22% upside) with some analysts projecting as high as $95<a href=\"https:\/\/stockanalysis.com\/stocks\/bbio\/forecast\/\">(Stock Analysis)<\/a>. \u2192 <strong>STRONG BUY<\/strong><\/li>\n<li><strong>2026 Projection:<\/strong> <strong>$44-52<\/strong> range &#8211; Some divergence emerges here with estimates between $35.01-$50.36, reflecting typical biotech volatility<a href=\"https:\/\/altindex.com\/ticker\/bbio\/price-prediction\">(AltIndex)<\/a>.<\/li>\n<li><strong>2028 Outlook:<\/strong> While specific 2028 forecasts aren&#8217;t widely published, the trajectory suggests <strong>$55-70<\/strong> potential if current commercial success continues.<\/li>\n<li><strong>2030 Long-Term:<\/strong> <strong>$22-36<\/strong> range &#8211; Longer-term forecasts show compression due to patent concerns and competition, but this represents excellent returns from current levels<a href=\"https:\/\/gov.capital\/stock\/bbio-stock\/\">(Gov Capital)<\/a>.<\/li>\n<\/ul>\n<p>The key takeaway? Near-term momentum is incredibly strong, making now an excellent entry point for investors comfortable with biotech volatility.<\/p>\n<h2>\u26a0\ufe0f Risk Assessment: What Could Go Wrong<\/h2>\n<ul>\n<li><strong>High Volatility Risk:<\/strong> BBIO has a beta of 0.88-0.94, meaning it can swing wildly on clinical trial news or regulatory decisions<a href=\"https:\/\/marketchameleon.com\/Overview\/BBIO\/Summary\/\">(Market Chameleon)<\/a>. A failed trial could easily drop the stock 30-50% in days.<\/li>\n<li><strong>Regulatory Dependency:<\/strong> The entire business hinges on FDA and EMA approvals. Any delays or rejections for pipeline drugs would be catastrophic.<\/li>\n<li><strong>Cash Burn Concerns:<\/strong> Despite recent revenue growth, the company still reported a $0.95 per share loss last quarter. They need continued commercial success to reach profitability<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/08\/05\/3127793\/0\/en\/BridgeBio-Reports-Second-Quarter-2025-Financial-Results-and-Business-Updates.html\">(Globe Newswire)<\/a>.<\/li>\n<li><strong>Competition Intensification:<\/strong> Larger pharma companies are increasingly targeting rare genetic diseases, potentially eroding BridgeBio&#8217;s first-mover advantage.<\/li>\n<\/ul>\n<h2>\ud83d\udfe2 Positive Signals: Why The Bull Case Is Strong<\/h2>\n<ul>\n<li><strong>Commercial Traction:<\/strong> Attruby generated $71.5 million in Q2 2025 net product revenue with 3,751 unique prescriptions already &#8211; nearly doubling from previous quarter<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/08\/05\/3127793\/0\/en\/BridgeBio-Reports-Second-Quarter-2025-Financial-Results-and-Business-Updates.html\">(Globe Newswire)<\/a>.<\/li>\n<li><strong>Financial Strength:<\/strong> $540.6 million cash position plus $300 million recent royalty monetization provides massive runway for development<a href=\"https:\/\/investor.bridgebio.com\/news\/news-details\/2025\/BridgeBio-Raises-300-Million-Through-Partial-Capped-Monetization-of-BEYONTTRA-European-Royalty\/default.aspx\">(BridgeBio Investor)<\/a>.<\/li>\n<li><strong>Pipeline Depth:<\/strong> Multiple Phase 3 programs including BBP-418 fully enrolled ahead of schedule, creating numerous potential catalysts<a href=\"https:\/\/investor.bridgebio.com\/overview\/default.aspx\">(BridgeBio Overview)<\/a>.<\/li>\n<li><strong>Analyst Support:<\/strong> 16 analysts cover BBIO with 7 Strong Buy and 9 Buy ratings &#8211; zero Hold or Sell recommendations<a href=\"https:\/\/stockanalysis.com\/stocks\/bbio\/forecast\/\">(Stock Analysis)<\/a>.<\/li>\n<\/ul>\n<h2>\ud83c\udfaf Beginner Trader Action Plan<\/h2>\n<p><strong>Today&#8217;s Smart Moves:<\/strong><\/p>\n<ol>\n<li><strong>Start Small<\/strong>: Allocate no more than 3-5% of your portfolio to BBIO initially &#8211; biotech is inherently risky<\/li>\n<li><strong>Dollar-Cost Average<\/strong>: Consider buying in increments rather than one lump sum to smooth out volatility<\/li>\n<li><strong>Set Alert for November<\/strong>: Mark your calendar for Q3 earnings &#8211; this could be your best entry point if there&#8217;s a post-earnings dip<\/li>\n<li><strong>Monitor Volume<\/strong>: High volume days often precede major moves &#8211; use them as additional entry signals<\/li>\n<\/ol>\n<p><strong>Humorous Veteran Insight:<\/strong> &#8220;Trading BBIO is like dating a brilliant scientist &#8211; incredibly rewarding but prone to dramatic mood swings based on experimental results. Don&#8217;t propose marriage on the first date!&#8221;<\/p>\n<h2>\u2705 Step-by-Step: How to Buy BridgeBio Pharma, Inc. (BBIO) Shares<\/h2>\n<table>\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Choose a Trading Platform<\/td>\n<td>Ensure it offers NASDAQ access and reasonable commission fees<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Complete Account Funding<\/td>\n<td>Start with an amount you&#8217;re comfortable risking &#8211; even $100 can get you started<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Search for &#8220;BBIO&#8221;<\/td>\n<td>Use the ticker symbol, not the company name, for accurate results<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Select Order Type<\/td>\n<td>Use limit orders to control your entry price rather than market orders<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Review and Confirm<\/td>\n<td>Double-check order details and fees before finalizing<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Why Pocket Option Makes Sense for BBIO Trading<\/h2>\n<p>For investors looking to trade BridgeBio Pharma, Inc. (BBIO) stock, Pocket Option offers several distinct advantages that align perfectly with biotech investing:<\/p>\n<ul>\n<li><strong>Minimum Deposit Flexibility<\/strong>: With just $5 required to start, you can test strategies with minimal risk before committing larger amounts to this volatile sector.<\/li>\n<li><strong>Rapid Account Verification<\/strong>: The 1-minute KYC process means you can capitalize on breaking news or sudden price movements without waiting days for account approval.<\/li>\n<li><strong>Diverse Withdrawal Options<\/strong>: Over 100 withdrawal methods ensure you can access profits quickly when BBIO makes those characteristic biotech spikes.<\/li>\n<\/ul>\n<p>This platform structure is particularly valuable for trading stocks like BBIO that can move 10-20% on single news events, allowing you to enter and exit positions with maximum flexibility.<\/p>\n<h2>\ud83e\uddec BridgeBio in 2025: Genetic Medicine Pioneer<\/h2>\n<p>BridgeBio Pharma has established itself as a commercial-stage biopharmaceutical company focused exclusively on developing transformative medicines for genetic diseases and certain cancers<a href=\"https:\/\/investor.bridgebio.com\/overview\/default.aspx\">(BridgeBio Overview)<\/a>. Founded in 2015, the company operates globally with a presence across North America and Europe.<\/p>\n<p>The company&#8217;s business model combines internal drug discovery with strategic partnerships, currently marketing four approved medicines while maintaining a robust pipeline across precision cardiorenal, mendelian diseases, precision oncology, and gene therapy<a href=\"https:\/\/investor.bridgebio.com\/overview\/default.aspx\">(BridgeBio Overview)<\/a>.<\/p>\n<p><strong>2025 Interesting Fact<\/strong>: BridgeBio&#8217;s drug Attruby achieved something remarkable &#8211; it generated 3,751 unique patient prescriptions within just nine months of FDA approval, with adoption growing at nearly 100% quarter-over-quarter<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/08\/05\/3127793\/0\/en\/BridgeBio-Reports-Second-Quarter-2025-Financial-Results-and-Business-Updates.html\">(Globe Newswire)<\/a>. This commercial velocity is virtually unprecedented in the rare disease space and demonstrates both medical need and execution excellence.<\/p>\n"},"faq":[{"question":"Is now a good time to buy BBIO stock?","answer":"With strong analyst support (16 Buys, zero Sells) and recent commercial momentum, current levels represent a reasonable entry point for long-term investors comfortable with biotech volatility."},{"question":"What's the biggest risk with BBIO?","answer":"Clinical trial failures pose the greatest risk - a negative result from any of their Phase 3 programs could drop the stock 30-50% quickly."},{"question":"How does BridgeBio make money?","answer":"Through product sales (Attruby generated $71.5M last quarter), partnership milestones, and royalty agreements with companies like Bayer."},{"question":"What makes BBIO different from other biotechs?","answer":"Their exclusive focus on genetic diseases creates specialized expertise, and they've successfully transitioned multiple drugs from development to commercialization."},{"question":"Should I hold through earnings reports?","answer":"Biotech earnings are notoriously volatile. Consider taking some profits before earnings if you have gains, or using options to hedge your position."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Is now a good time to buy BBIO stock?","answer":"With strong analyst support (16 Buys, zero Sells) and recent commercial momentum, current levels represent a reasonable entry point for long-term investors comfortable with biotech volatility."},{"question":"What's the biggest risk with BBIO?","answer":"Clinical trial failures pose the greatest risk - a negative result from any of their Phase 3 programs could drop the stock 30-50% quickly."},{"question":"How does BridgeBio make money?","answer":"Through product sales (Attruby generated $71.5M last quarter), partnership milestones, and royalty agreements with companies like Bayer."},{"question":"What makes BBIO different from other biotechs?","answer":"Their exclusive focus on genetic diseases creates specialized expertise, and they've successfully transitioned multiple drugs from development to commercialization."},{"question":"Should I hold through earnings reports?","answer":"Biotech earnings are notoriously volatile. Consider taking some profits before earnings if you have gains, or using options to hedge your position."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy BridgeBio Pharma, Inc. (BBIO) shares - Investment in BridgeBio Pharma, Inc. (BBIO) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy BridgeBio Pharma, Inc. (BBIO) shares - Investment in BridgeBio Pharma, Inc. (BBIO) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-20T14:08:54+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy BridgeBio Pharma, Inc. (BBIO) shares &#8211; Investment in BridgeBio Pharma, Inc. (BBIO) stock\",\"datePublished\":\"2025-08-20T14:08:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/\"},\"wordCount\":17,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/\",\"name\":\"How to buy BridgeBio Pharma, Inc. (BBIO) shares - Investment in BridgeBio Pharma, Inc. (BBIO) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"datePublished\":\"2025-08-20T14:08:54+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy BridgeBio Pharma, Inc. (BBIO) shares &#8211; Investment in BridgeBio Pharma, Inc. (BBIO) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy BridgeBio Pharma, Inc. (BBIO) shares - Investment in BridgeBio Pharma, Inc. (BBIO) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/","og_locale":"en_US","og_type":"article","og_title":"How to buy BridgeBio Pharma, Inc. (BBIO) shares - Investment in BridgeBio Pharma, Inc. (BBIO) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-20T14:08:54+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy BridgeBio Pharma, Inc. (BBIO) shares &#8211; Investment in BridgeBio Pharma, Inc. (BBIO) stock","datePublished":"2025-08-20T14:08:54+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/"},"wordCount":17,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/","name":"How to buy BridgeBio Pharma, Inc. (BBIO) shares - Investment in BridgeBio Pharma, Inc. (BBIO) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","datePublished":"2025-08-20T14:08:54+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-bridgebio-pharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy BridgeBio Pharma, Inc. (BBIO) shares &#8211; Investment in BridgeBio Pharma, Inc. (BBIO) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":341228,"slug":"how-to-buy-bridgebio-pharma","post_title":"Comment acheter des actions BridgeBio Pharma, Inc. (BBIO) - Investir dans les actions BridgeBio Pharma, Inc. (BBIO)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-bridgebio-pharma\/"},"it_IT":{"locale":"it_IT","id":341223,"slug":"how-to-buy-bridgebio-pharma","post_title":"Come acquistare azioni BridgeBio Pharma, Inc. (BBIO) - Investire in azioni BridgeBio Pharma, Inc. (BBIO)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-bridgebio-pharma\/"},"pl_PL":{"locale":"pl_PL","id":341224,"slug":"how-to-buy-bridgebio-pharma","post_title":"Jak kupi\u0107 akcje BridgeBio Pharma, Inc. (BBIO) - Inwestycja w akcje BridgeBio Pharma, Inc. (BBIO)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-bridgebio-pharma\/"},"es_ES":{"locale":"es_ES","id":341226,"slug":"how-to-buy-bridgebio-pharma","post_title":"C\u00f3mo comprar acciones de BridgeBio Pharma, Inc. (BBIO) - Inversi\u00f3n en acciones de BridgeBio Pharma, Inc. (BBIO)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-bridgebio-pharma\/"},"th_TH":{"locale":"th_TH","id":341229,"slug":"how-to-buy-bridgebio-pharma","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 BridgeBio Pharma, Inc. (BBIO) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 BridgeBio Pharma, Inc. (BBIO)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-bridgebio-pharma\/"},"tr_TR":{"locale":"tr_TR","id":341225,"slug":"how-to-buy-bridgebio-pharma","post_title":"BridgeBio Pharma, Inc. (BBIO) Hisseleri Nas\u0131l Al\u0131n\u0131r - BridgeBio Pharma, Inc. (BBIO) Hisse Senedi Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-bridgebio-pharma\/"},"vt_VT":{"locale":"vt_VT","id":341230,"slug":"how-to-buy-bridgebio-pharma","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu BridgeBio Pharma, Inc. (BBIO) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu BridgeBio Pharma, Inc. (BBIO)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-bridgebio-pharma\/"},"pt_AA":{"locale":"pt_AA","id":341227,"slug":"how-to-buy-bridgebio-pharma","post_title":"Como comprar a\u00e7\u00f5es da BridgeBio Pharma, Inc. (BBIO) - Investimento em a\u00e7\u00f5es da BridgeBio Pharma, Inc. (BBIO)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-bridgebio-pharma\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/341163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=341163"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/341163\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334117"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=341163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=341163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=341163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}